Uromigos-ASCO

Advertisement
The UromigosThe Uromigos | June 10, 2024
Silke Gillessen joins Tom and Brian, who give their opinion on new data presented at the conference.
Listen Now
The UromigosThe Uromigos | June 6, 2024
David McDermott discusses the adjuvant vs neoadjuvant trial and its wider implications for the genitourinary oncology field.
The UromigosThe Uromigos | June 6, 2024
Dr. Guru Sonpavde describes the efficacy of chemotherapy with nivolumab in lymph node-only first-line UC patients.
The UromigosThe Uromigos | June 21, 2024
Dr. Laurence Albiges discusses this biomarker which may have predictive and prognostic capabilities for kidney cancer.
The UromigosThe Uromigos | June 21, 2024
Toni Choueiri and Brian describe similarities and differences in the biomarker findings of the KN426 and CLEAR trials.
The UromigosThe Uromigos | June 11, 2024
Dr. Andrea Necchi describes the efficacy and toxicity of neoadjuvant sacituzumab govitecan in urothelial carcinoma.
The UromigosThe Uromigos | June 11, 2024
Dr. Jonathan Rosenberg breaks down the data available for the bladder cohort from the DESTINY-PanTumor02 trial.
The UromigosThe Uromigos | June 6, 2024
Dr. Alex Wyatt describes the predictive capabilities of ctDNA in determining outcomes in the TheraP trial.
The UromigosThe Uromigos | June 6, 2024
Dr. Christos Kyriakopoulos describes the outcome of the CHAARTED-2 study for castration-resistant prostate cancer.
The UromigosThe Uromigos | June 6, 2024
Silke Gillessen joins Brian and Tom to give a preview of this year's ASCO annual meeting.
The UromigosThe Uromigos | July 17, 2023
Yohann Loriot, MD, PhD, discusses the practice-changing THOR study data on the benefit of erdafitinib for advanced UC.
The UromigosThe Uromigos | July 25, 2023
Meredith Regan and David McDermott finalize their debate on VEGF/TKI vs IPI/NIVO for mRCC. PFS2 and TFS are also covered.
The UromigosThe Uromigos | June 21, 2023
Silke Gillessen, MD, PhD joins The Uromigos to discuss the genitourinary oncology highlights of ASCO 2023.
The UromigosThe Uromigos | June 21, 2023
The Uromigos discuss ipi/nivo combination therapy versus VEGF TKI I/O immune therapy for ccRCC with Mike Atkins, MD.
The UromigosThe Uromigos | July 10, 2023
Shilpa Gupta, MD discusses two oral abstracts from ASCO 2023 on the CONTACT-03 trial and the EV-103 trial.
The UromigosThe Uromigos | August 1, 2023
Toni Choueiri gives an overview of the CONTACT-03 trial on atezolizumab plus cabozantinib versus cabozantinib alone for mRCC.
The UromigosThe Uromigos | August 1, 2023
Karim Fizazi, MD, PhD, discusses the radiotherapy components of the PEACE-1 study on abiraterone and prednisone added to ADT.
The UromigosThe Uromigos | August 1, 2023
Karim Fizazi joins us at ASCO 2023 to discuss results from the TALAPRO-2 study on talazoparib plus enzalutamide for mCRPC.
The UromigosThe Uromigos | August 1, 2023
Drs. David McDermott and Meredith Regan discuss statistics in clinical trials and upcoming RCC presentations at ASCO 2023.
The UromigosThe Uromigos | August 1, 2023
We chat with Christopher Sweeney about the upcoming ASCO 2023 conference and what presentations to look out for.
Advertisement
Advertisement
Advertisement